Plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy

Circulation

Volumn 129, Issue 12, 2014, Pages 1320-1331

  Tersteeg, Claudia ^a   De Maat, Steven ^a   De Meyer, Simon F ^b   Smeets, Michel W J ^a   Barendrecht, Arjan D ^a   Roest, Mark ^a   Pasterkamp, Gerard ^a   Fijnheer, Rob ^a   Vanhoorelbeke, Karen ^b   De Groot, Philip G ^a   Maas, Coen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

fibrinolysis; plasminogen; platelets; streptokinase; urokinase; von Willebrand factor

Indexed keywords

ALPHA 2 ANTIPLASMIN; LYSINE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; STREPTOKINASE; UROKINASE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMAN; HUMAN CELL; MALE; MICROSCOPY; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DOMAIN; THROMBOCYTE; THROMBOCYTE AGGLUTINATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

FIBRINOLYSIS; PLASMINOGEN; PLATELETS; STREPTOKINASE; UROKINASE; VON WILLEBRAND FACTOR;

ADAM PROTEINS; ANIMALS; AUTOANTIBODIES; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBRINOLYSIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR WEIGHT; PLASMINOGEN; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STREPTOKINASE; THROMBOTIC MICROANGIOPATHIES; VON WILLEBRAND FACTOR;

EID: 84897114562     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.006727     Document Type: Article

References (26)

1. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, López JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039.
2. Fujimura Y, Titani K, Holland LZ, Russell SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS. von Willebrand factor: a reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem. 1986;261:381-385.
3. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
4. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood. 2008;111:651-657.
5. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
6. Groot E, Fijnheer R, Sebastian SA, de Groot PG, Lenting PJ. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost. 2009;7:962-969.
7. Berkowitz SD, Dent J, Roberts J, Fujimura Y, Plow EF, Titani K, Ruggeri ZM, Zimmerman TS. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. J Clin Invest. 1987;79:524-531.
8. Wohner N, Kovács A, Machovich R, Kolev K. Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways. Thromb Res. 2012;129:e41-e46.
9. van Zonneveld AJ, Veerman H, MacDonald ME, van Mourik JA, Pannekoek H. Structure and function of human tissue-type plasminogen activator (t-PA). J Cell Biochem. 1986;32:169-178.
10. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129:307-321.
11. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol. 2009;29:1151-1155.
12. Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VW. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood. 2000;96:2775-2783.
13. Graham CH, Fitzpatrick TE, McCrae KR. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood. 1998;91:3300-3307.
14. Hollestelle MJ, Lai KW, van Deuren M, Lenting PJ, de Groot PG, Sprong T, Bovenschen N. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS One. 2011;6:e24216.
15. Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, Scheiflinger F, Schwarz HP, Muchitsch EM. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119:6128-6135.
16. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjöbring U, Ginsburg D. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004;305:1283-1286.
17. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118:3212-3221.
18. Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells: a potential target for the anti-angiogenic action of angiostatin. J Biol Chem. 2002;277:33564-33570.
19. Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR 3rd, Parmer RJ, Miles LA. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood. 2010;115:1319-1330.
20. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985;65:32-40.
21. Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, Lijnen HR, Vanhoorelbeke K. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:2053-2062.
22. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood. 1979;53:313-324.
23. Collen D, de Maeyer L. Molecular biology of human plasminogen, I: physiochemical properties and microheterogeneity. Thromb Diath Haemorrh. 1975;34:396-402.
24. Furlan M, Furlan M, Robles R, Robles R, Galbusera M, Galbusera M, Remuzzi G, Remuzzi G, Kyrle PA, Kyrle PA, Brenner B, Brenner B, Krause M, Krause M, Scharrer I, Scharrer I, Aumann V, Aumann V, Mittler U, Mittler U, Solenthaler M, Solenthaler M, Lämmle B, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
25. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115:2752-2761.
26. Kakishita E, Koyama T, Higuchi M, Kunitomi O, Oura Y, Nagai K. Fibrinogenolysis in thrombotic thrombocytopenic purpura. Am J Hematol. 1989;32:14-19.